SSRIs in Pregnancy: New Study Reveals Mixed Health Outcomes
An international research effort has identified complex associations between the use of Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants during pregnancy and various maternal and newborn health outcomes. Utilizing extensive national registry data, the study found links to both increased and decreased risks for specific conditions, even after accounting for maternal depression.
The research suggests SSRI use during pregnancy is associated with an increased risk of gestational diabetes and early adaptation issues in newborns, while potentially reducing the risks of preterm birth, low birth weight, and caesarean sections.
Key Findings
The study highlighted several specific associations:
- Gestational Diabetes: An increased risk was identified among women using SSRIs during pregnancy, compared to women with depression who did not use antidepressant medication.
- Newborn Adaptation Problems: Newborns exposed to SSRIs in utero showed increased risks of lower Apgar scores at 1 and 5 minutes, breathing problems, and the requirement for neonatal care or neonatal intensive care unit (NICU) treatment. These effects were observed independently of maternal depression.
- Reduced Risks: Conversely, SSRI medication use during pregnancy was associated with a lower risk of late preterm birth, very preterm birth, low birth weight, very low birth weight, and caesarean sections.
- Major Congenital Malformations: Significantly, the study found no increased risk of major congenital malformations.
Detailed Comparisons
When comparing women who continued SSRI use during pregnancy to those who discontinued the medication before pregnancy, continued use was associated with a lower risk of late preterm birth and low birth weight. However, the elevated risks for early adaptation problems in newborns remained present in this comparison.
Expert Insight
Docent Heli Malm, the lead author of the study, emphasized the critical importance of individualized treatment decisions during pregnancy.
"Treating depression is important, and SSRI use appears to offer protection against preterm birth risks associated with depression," Malm stated.
She also stressed the need for close monitoring of both pregnancy progression and the newborn's health. Malm noted that further research is required to clarify the association with gestational diabetes, including potential cause-and-effect relationships and underlying biological mechanisms.
Study Methodology
This extensive population-based study was a collaborative effort between the Research Centre for Child Psychiatry at the University of Turku, Finland, and Columbia University in New York. Researchers utilized national registry data encompassing over 1.27 million children born in Finland between 1996 and 2018.
The study employed multiple comparison groups to differentiate the effects of the medication from those of underlying maternal depression and its severity. These groups included:
- Mothers who used SSRIs during pregnancy.
- Women diagnosed with depression who did not use antidepressants during pregnancy.
- Women who had discontinued SSRI use prior to pregnancy.
Sibling comparisons were also utilized to account for hereditary and environmental factors, aiming to determine if previously reported prenatal risks were attributable to the medications or to maternal depression and its severity. The analyses adjusted for several indicators of depression severity.